Korean J Urol.  2009 Feb;50(2):154-158.

Effects of Subclinical Prostatitis on Benign Prostatic Hyperplasia

• Kim HW
• Kim SH
• Kim SW
• Jung KI
• Min KO
• Cho SY

Abstract

PURPOSE
Subclinical prostatitis is a very frequent histologic finding in pathological examinations of prostate surgery specimens. We evaluated the correlation between the symptoms of benign prostatic hyperplasia (BPH) and the grades of inflammation in surgical specimens of patients who had undergone operation for BPH without any evidence of clinical prostatitis.
MATERIALS AND METHODS
Seventy five patients with BPH, who had gone through transurethral resection of the prostate (TURP) at our department from March 2004 to May 2007, were retrospectively studied. Of the 75 patients, 57 patients were pathologically diagnosed as having a BPH with prostatitis and 18 patients had the only BPH (group G0). Chronic inflammation was graded as I (group G1: scattered inflammatory cell infiltrate within the stroma without lymphoid nodules), II (group G2: nonconfluent lymphoid nodules) or III (group G3: large inflammatory areas with confluence of infiltrate). The serum prostate-specific antigen (PSA) level, PSA density (PSAD), International Prostate Symptom Score (IPSS) and maximum urinary flow rate were compared among the grades of inflammation.
RESULTS
In the patients had undergone TURP, prostatic inflammation was found in 76% (57/75). The storage symptoms of IPSS and PSAD were significantly correlated to the extent of inflammation in each groups (p<0.05). No significant correlations were observed between PSA, size of prostate, voiding symptoms, quality of life (QoL) of IPSS, and maximum urinary flow rate.
CONCLUSIONS
The extent of chronic inflammation had considerably more relationship with storage symptoms than voiding symptoms and with the increased PSAD. These findings suggest that the subclinical prostatitis may be one of the factors of storage symptoms of BPH patients and postoperative maintained lower urinary tract symptoms.

Keyword

Prostatitis; Benign prostatic hyperplasia; Symptoms

MeSH Terms

Humans
Inflammation
Lower Urinary Tract Symptoms
Prostate
Prostate-Specific Antigen
Prostatic Hyperplasia
Prostatitis
Quality of Life
Retrospective Studies
Transurethral Resection of Prostate
Prostate-Specific Antigen

Figure

• 

  Fig. 1 Extent of chronic inflammation in transurethral resection of the prostate (TURP) specimens (H&E, ×100). (A) Grade O, (B) Grade I, (C) Grade II, (D) Grade III.

Reference

1. Chung TG, Chung J, Lee MS, Ahn H. Prevalence of benign prostatic hyperplasia in Jeong-up area: community-based study. Korean J Urol. 1999. 40:52–58.

2. Woo YN. Prostatitis. Korean J Urol. 1994. 35:575–585.

3. Nickel JC, Downey J, Hunter D, Clark J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol. 2001. 165:842–845.

4. Nickel JC. Prostatic inflammation in benign prostatic hyperplasia-the third component? Can J Urol. 1994. 1:1–4.

5. Nickel JC. The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Curr Opin Urol. 2006. 16:5–10.

6. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol. 1979. 121:755–760.

7. Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostatic specific antigen value. J Urol. 1997. 157:1301–1303.

8. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993. 150:85–89.

9. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol. 1986. 136:1–4.

10. Shapiro E, Lepor H. Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am. 1995. 22:285–290.

11. McConnell JD. Benign prostatic hyperplasia. Hormonal treatment. Urol Clin North Am. 1995. 22:387–400.

12. Lepor H. Alpha blockade for the treatment of benign prostatic hyperplasia. Urol Clin North Am. 1995. 22:375–386.

13. Emberton M, Elhilali M, Matzkin H, Harving N, van Moorselaar J, Hartung R, et al. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10mg once daily. Urology. 2005. 66:316–322.

14. Stoner E. The clinical development of a 5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol. 1990. 37:375–378.

15. Kaplan SA, Te AE, Pressler LB, Olsson CA. Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure. J Urol. 1995. 154:1764–1769.

16. Lee SO, Cho IR, Lee KC, Kim HS. Elevation of serum prostate specific antigen in subclinical prostatitis: the role of pathology of inflammation. Korean J Urol. 2006. 47:31–36.

17. Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int. 2007. 100:327–331.

18. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol. 1979. 121:755–760.

19. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008. 54:1379–1384.

20. Lee SY, Park YY. Clinical characteristics of the associated histopathological findings in benign prostatic hyperplasia. Korean J Urol. 1991. 32:915–920.

21. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999. 84:976–981.

22. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol. 2006. 16:25–29.

23. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol. 2006. 164:760–768.

24. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate. 2002. 52:43–58.

25. Handisurya A, Steiner GE, Stix U, Ecker RC, Pfaffeneder-Mantai S, Langer D, et al. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate. 2001. 49:251–262.

26. Roehrborn CG, Kaplan SA, Noble WD, Slawin KM, McVary KT, Kusek JW. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH. Results from the MTOPS study. J Urol. 2005. 173:Suppl. abstract 1277.

27. Okada K, Kojima M, Naya Y, Kamoi K, Yokoyama K, Takamatsu T, et al. Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology. 2000. 55:892–898.

28. Moser PL, Brunner A, Horninger W, Bartsch G, Mikuz G. Correlation between inflammatory cells (T and B lymphocytes, macrophages) in prostate biopsies and elevated PSA levels in a PSA screening population. Urology. 2002. 59:68–72.

29. Ozden C, Ozdal OL, Guzel O, Han O, Seckin S, Memis A. The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. Int Urol Nephrol. 2007. 39:859–863.